The prognostic value of IL-8 for the death of severe or critical patients with COVID-19

Li, Hui; Zhang, Jun; Chen, Fang; Zhao, Xuming; Qi, Bin; Sun, Yihui; Zhou, Yan; Hu, Ji; Huang, Yun; Ma, Qi; Hui, Jie

doi:10.1097/md.0000000000023656

Cited by 25 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the CRP levels were gently reduced from day 0 to day 6 in both groups of patients. Our finding confirms previous investigations demonstrating that the IL-6 [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , IL-8 [51] , [52] , [53] , [54] , and CRP [55] , [56] were significantly elevated in patients with COVID-19. Besides, our results revealed that the concentrations of IL-4 and IL-10 were significantly elevated in cases with COVID-19 than in HS.…”

Section: Discussionsupporting

confidence: 92%

A possible pathogenic correlation between neutrophil elastase (NE) enzyme and inflammation in the pathogenesis of coronavirus disease 2019 (COVID-19)

Karampoor

Hesamizadeh

Maleki

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

A growing body of evidence indicates that neutrophil elastase (NE) is involved in the pathogenesis of respiratory infectious diseases, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to analyze the dynamic changes in serum levels of NE associated with inflammation, disease activity, and mortality rate in patients with COVID-19. We measured the serum concentrations of NE, C-Reactive protein (CRP), interleukin (IL)- 4, IL-6, IL-8, IL-10, and vitamin D levels in 83 ICU and 69 non-ICU patients compared with 82 healthy subjects (HS) in three-time points (T1-T3). Serum levels of NE, IL-6, IL-8, and CRP in ICU and non-ICU patients were significantly higher than HS ( P <0.001) in three-time points. Also, serum levels of NE, IL-6, IL-8, and CRP in ICU patients were significantly higher than in non-ICU patients ( P <0.05). On the day of admission (T1), the levels of NE, CRP, IL-6, IL-8 were gradually decreased from T1 to T3. At the same time, IL-4 and IL-10 were gradually increased from T1 to T2 and then reduced to T3. Further analyses demonstrated that the levels of NE, IL-6, and IL-8 in deceased patients were significantly higher than in recovered patients ( P <0.05). The ROC curve analysis demonstrated that markers, including NE, IL-6, and IL-8, were valuable indicators in evaluating the activity of COVID-19. Overall, our results signify the critical role of NE in the pathogenesis of COVID-19, and also, further support that NE has a potential therapeutic target for the attenuation of COVID-19 severity.

show abstract

Section: Discussionsupporting

confidence: 92%

A possible pathogenic correlation between neutrophil elastase (NE) enzyme and inflammation in the pathogenesis of coronavirus disease 2019 (COVID-19)

Karampoor

Hesamizadeh

Maleki

et al. 2021

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“… 29 IL-8, a biomarker of COVID-19 severity, 30 has been related to a longer disease duration 31 and is inversely correlated with the time from admission to death. 32 Furthermore, high levels of IL-8 are associated with elevated D-dimer and decreased PaO2/FiO2 ratio. This chemokine induces neutrophil degranulation, promoting a pro-thrombotic state.…”

Section: Discussionmentioning

confidence: 99%

Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)

et al. 2021

View full text Add to dashboard Cite

Background Colchicine is an available, safe, and effective anti-inflammatory drug and has been suggested as a COVID-19 treatment, but its usefulness in hospitalized severe COVID-19 patients has not been thoroughly demonstrated. Objective To address the safety and efficacy of colchicine in hospitalized patients with severe COVID-19. Design We conducted a triple-blind parallel non-stratified placebo-controlled clinical trial. Participants We recruited 116 hospitalized patients with severe COVID-19 in Mexico. Interventions Patients were randomized to receive 1.5 mg of colchicine or placebo at the time of the recruitment in the study (baseline) and 0.5 mg BID PO to complete 10 days of treatment. Main Measures The primary composite outcome was the progression to critical disease or death. Besides, we evaluated immunological features at baseline and after recovery or disease progression in 20 patients. Key Results Fifty-six patients were allocated to colchicine and 60 patients received placebo. The study was suspended after the second interim analysis demonstrated colchicine had no effect on the primary outcome (OR 0.83, 95%CI 0.35–1.93, P = 0.67), nor in the days of ICU and hospital stays. Adverse events were similar between groups (OR 1.63, 95% CI 0.66–3.88, P = 0.37). After colchicine treatment, patients had higher BUN and lower serum levels of IL-8, IL-12p70, and IL-17A. Conclusions Colchicine is safe but not effective in the treatment of severe COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04367168.

show abstract

“…Elevated concentrations of IL-1ra, IL-8, IL-10, MCP-1, SCF, and CA-9 resulted in a 92.9% correct classification of cases in our cohort that died during the progression of COVID-19. While IL-8, and MCP-1 have already been used to predict disease severity and survival, 8,11,12,25,26 the combination with new markers like SCF and CA-9 is a novel finding of this work. Elevated MCP-1 concentrations are linked with IL-6 induced elevation of PAI-1 and endothelial dysfunction, that has been shown to be a major driver for disease severity in COVID-19.…”

Section: Dovepressmentioning

confidence: 97%

Distinct Patterns of Blood Cytokines Beyond a Cytokine Storm Predict Mortality in COVID-19

Herr¹,

Mang²,

Mozafari³

et al. 2021

JIR

View full text Add to dashboard Cite

Background: COVID-19 comprises several severity stages ranging from oligosymptomatic disease to multi-organ failure and fatal outcomes. The mechanisms why COVID-19 is a mild disease in some patients and progresses to a severe multi-organ and often fatal disease with respiratory failure are not known. Biomarkers that predict the course of disease are urgently needed. The aim of this study was to evaluate a large spectrum of established laboratory measurements.Patients and Methods: Patients from the prospective PULMPOHOM and CORSAAR studies were recruited and comprised 35 patients with COVID-19, 23 with conventional pneumonia, and 28 control patients undergoing elective non-pulmonary surgery. Venous blood was used to measure the serum concentrations of 79 proteins by Luminex multiplex immunoassay technology. Distribution of biomarkers between groups and association with disease severity and outcomes were analyzed. Results: The biomarker profiles between the three groups differed significantly with elevation of specific proteins specific for the respective conditions. Several biomarkers correlated significantly with disease severity and death. Uniform manifold approximation and projection (UMAP) analysis revealed a significant separation of the three disease groups and separated between survivors and deceased patients. Different models were developed to predict mortality based on the baseline measurements of several protein markers. A score combining IL-1ra, IL-8, IL-10, MCP-1, SCF and CA-9 was associated with significantly higher mortality (AUC 0.929). Discussion: Several newly identified blood markers were significantly increased in patients with severe COVID-19 (AAT, EN-RAGE, myoglobin, SAP, TIMP-1, vWF, decorin) or in patients that died (IL-1ra, IL-8, IL-10, MCP-1, SCF, CA-9). The use of established assay technologies allows for rapid translation into clinical practice.

show abstract

The prognostic value of IL-8 for the death of severe or critical patients with COVID-19

Cited by 25 publications

References 14 publications

A possible pathogenic correlation between neutrophil elastase (NE) enzyme and inflammation in the pathogenesis of coronavirus disease 2019 (COVID-19)

A possible pathogenic correlation between neutrophil elastase (NE) enzyme and inflammation in the pathogenesis of coronavirus disease 2019 (COVID-19)

Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID)

Distinct Patterns of Blood Cytokines Beyond a Cytokine Storm Predict Mortality in COVID-19

Contact Info

Product

Resources

About